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www.aacrJunctional adhesion molecule-A (JAM-A)–null dendritic cells (DCs) are more motile and effective than their
wild-type counterpart in promoting contact hypersensitivity reaction. Here, we show that the growth and ag-
gressiveness of pancreatic islet cell carcinoma induced by SV40 T antigen expression in β cells (Rip1Tag2
mice) are significantly reduced in JAM-A–null mice. Because these tumor cells do not express JAM-A, we fo-
cused on changes in stroma reactivity. In the absence of JAM-A, tumors showed a small but significant reduc-
tion in angiogenesis and a marked increase in the immune reaction with enhanced infiltration of DCs (CD11c+
and MHC-II+) and CD4+ and CD8+ lymphocytes. In contrast, phagocyte number was not affected. DC capacity
to produce cytokines was not significantly altered, but transmigration through JAM-A–null endothelial cells
was increased as compared with JAM-A–positive endothelium. On adoptive transfer, JAM-A−/− DCs were re-
cruited to tumors at slightly but significantly higher rate than JAM-A+/+ DCs. Ablation of CD4+ and CD8+ cells
with specific antibodies abrogated the inhibitory effect of JAM-A deletion on tumor growth and angiogenesis.
These findings support the idea that, in the Rip1Tag2 tumor model, abrogation of JAM-A reduces cancer de-
velopment by increasing antitumor immune response. Cancer Res; 70(5); 1759–65. ©2010 AACR.Introduction
Junction adhesion molecule-A (JAM-A) is a transmem-
brane small immunoglobulin-like molecule expressed at en-
dothelial and epithelial tight junctions (1–4). JAM-A is also
present on leukocytes where it promotes cell adhesion and
motility (1–5). Genetic or antibody-mediated inactivation of
JAM-A in mice reduced neutrophil or monocyte infiltration
in several models of inflammation such as meningitis, perito-
nitis, and heart and liver ischemia-reperfusion injury (1–5). In
contrast to phagocytes, JAM-A–null dendritic cells (DCs) ex-
hibit increased motility on extracellular matrix proteins and
through lymphatic endothelium (6). Consistently, in JAM-A–
null mice, DCs move more effectively to lymph nodes and
promote enhanced contact hypersensitivity reaction (6). Al-
though the reason for the discrepant behavior of JAM-A in
dendritic and inflammatory cells is not fully clear yet, a likely
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cancerres.aacrjoDownloaded from tissue stroma follows a different molecular mechanism than
that of neutrophils or monocytes (7).
DCs work as antigen-presenting cells promoting T lym-
phocyte clonal expansion and initiating the adaptive immune
response (8). These cells, therefore, may also promote host
immunologic reaction against tumors. We crossed Rip1Tag2
mice, which express SV40 T antigen under the control of
the rat insulin promoter, with JAM-A−/− mice. Rip1Tag2 mice
develop pancreatic islet hyperplasia and highly vascularized
adenomas, which progress to invasive carcinomas (9). Impor-
tantly, tumor cells in Rip1Tag2 mice do not express JAM-A at
any stage of progression, allowing the study of the specific
role of JAM-A in the cells of the tumor stroma.
The present study shows that Rip1Tag2 tumors grow less
in JAM-A−/− mice, and this effect is accompanied by en-
hanced infiltration of DCs and CD8+ and CD4+ T cells and
reduced angiogenesis. T-cell infiltration is required for the
inhibition of tumor growth in JAM-A−/− mice, implying that
the loss of JAM-A promotes a stronger immunologic re-
sponse against the tumor.Materials and Methods
Animals. Rip1Tag2 transgenic mice were generated by
D. Hanahan (University of California, San Francisco, San
Francisco, CA; ref. 9) and provided by G. Christofori (Uni-
versity of Basel, Basel, Switzerland). They were crossed
with JAM-A−/− mice (6) to obtain a Rip1Tag2;JAM-A−/−1759
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Published OnlineFirst February 16, 2010; DOI:10.1158/0008-5472.CAN-09-1703strain. Rip1Tag2;JAM-A+/+ littermates, obtained during
breeding of the two strains, were used as control.
Histopathologic analysis. Histologic analysis was done as
described (10). The following antibodies were used: CD4
(L3T4), CD8a (Ly2), CD11b (Mac-1), CD11c (N418), and
MHC class II (MHC-II) were purchased from BD Biosciences.
CD31 [platelet endothelial cell adhesion molecule-1 (PE-
CAM1)], CD68, F4/80, and Ki-67 were obtained from Chemi-
con, Hycult Biotechnology, Serotec, and Abcam, respectively.
TdT-mediated dUTP nick end labeling (TUNEL) staining was
done using the In Situ Cell Death Detection Kit (Roche).
Assessment of tumor burden and tumor number. The
length and width of each pancreas tumor were measured mi-
croscopically. The formula 0.5 width × 0.5 length × π for ap-
proximating the area was applied.
Flow cytometry analysis. Pancreatic islet tumor and peri-
pancreatic lymph nodes were isolated under a stereomicro-
scope. Single-cell suspensions were stained and analyzed
with a FACSCalibur (CellQuest software, BD Biosciences).
DC adoptive transfer. Murine DCs were generated from
bone marrow of JAM-A+/+ and JAM-A−/− mice as previously de-
scribed (11). DCs were then incubated with carboxyl-fluorescein-
succinimidyl ester (CFSE; Molecular probes) or Far Red
DDAO-SE (Molecular probes) for labeling. Green CFSE–Cancer Res; 70(5) March 1, 2010
American Asso Copyright © 2010 
cancerres.aacrjoDownloaded from labeled JAM-A+/+ DCs and Far Red DDAO-SE–labeled JAM-A−/−
DCs (1 × 107) were injected i.p. in Rip1Tag2 mice. Mice were
sacrificed 48 h after injection, and pancreas specimens were
collected for analysis of cell infiltration.
Transmigration assay. JAM-A–null endothelial cells or
JAM-A–null endothelial cells reconstituted with full-length
JAM-A cDNA (12) were seeded on 5-μm-pore-size filters of
24-well Transwell plates (Costar). Purified DCs were seeded
on endothelial monolayers and cell migration was evaluated
as described previously (6, 11).
Antibody treatment. Antibodies (50 μg) neutralizing CD4
(clone GK1.5) and CD8 (clone 2.43) and rat IgG isotype control
(Sigma) were injected i.p. twice a week in Rip1Tag2;JAM-A+/+
or Rip1Tag2;JAM-A−/− mice between the age of 4 and 10 wk.
Statistical analysis. Statistical significance was evaluated
by paired or unpaired Student's t test. Significance was defined
atP < 0.05 (*) andP < 0.01 (**). Statistical calculations andKaplan-
Meier's curves were done with JMP 5.1 software (SAS Cary).
Results
Rip1Tag2;JAM-A−/− mice show decreased tumor progres-
sion and aggressiveness. By immunofluorescence staining,
JAM-A was shown in epithelia of normal pancreatic exocrineFigure 1. Rip1Tag2(RT);JAM-A−/− mice show decreased islet tumor growth. A, JAM-A staining of RT JAM-A+/+ and RT JAM-A−/− mice. Bar, 100 μm.
B, representative H&E staining of pancreas specimens of 13-wk-old mice. The dotted line encircles islet tumors. Bar, 4 mm (top) and 100 μm (bottom).
C, quantification of tumor and carcinoma number and cumulative area of islet tumors. Columns, mean of 13 RT JAM-A+/+ and 11 RT JAM-A−/− mice;
bars, SEM. D, life span of RT JAM-A+/+ and RT JAM-A−/− (n = 58 and 20, respectively).Cancer Research
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Published OnlineFirst February 16, 2010; DOI:10.1158/0008-5472.CAN-09-1703ducts and endothelia of tumor-associated vessels in Rip1-
Tag2;JAM-A+/+ mice, whereas it was absent in tumor cells.
Several cell types infiltrating the tumor stroma were positive
for JAM-A expression, such as DCs, monocyte/macrophages,
and CD4 and CD8 lymphocytes (Supplementary Fig. S1).
As expected, JAM-A was undetectable in any cell type of
Rip1Tag2;JAM-A−/− mice (Fig. 1A; Supplementary Fig. S1).
Thirteen-week-old Rip1Tag2;JAM-A+/+ mice developed
around 20 islet tumors per mouse, about 50% of which
showed carcinoma features (Fig. 1B). Rip1Tag2;JAM-A−/−
mice exhibited lower tumor incidence, smaller tumor size,
and lower rate of progression to invasive carcinoma (Fig.
1B and C). In the absence of JAM-A, a small increase in
mouse survival was also observed (Fig. 1D) although the dif-
ference did not reach statistical significance (P = 0.07). This
weak difference may be due to the fact that Rip1Tag2 mice
die not only of the tumor burden but also of high insulin lev-
els (9). Abrogation of JAM-A expression caused a significant
decrease in vascular density (Fig. 2A) and an increase in tu-
mor cell apoptosis, whereas tumor cell proliferation was un-
affected (Fig. 2C and B, respectively). Endothelial cell
apoptosis, growth, and permeability to dextran (Supplemen-
tary Figs. S2 and S3) were unaffected by the lack of JAM-A.
The loss of JAM-A enhances tumor infiltration by DCs
and CD4+ and CD8+ T lymphocytes. Tumor infiltration of
DCs (MHC-II+ and CD11c+) was higher in Rip1Tag2;JAM-A−/−www.aacrjournals.org
American Asso Copyright © 2010 
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was observed in the number of infiltrated phagocytes (F4/80+
and CD11b+; Fig. 3A and B). Consistently, peripancreatic lymph
nodes showed higher infiltration of CD11c+ cells, but not CD11b+
cells (Fig. 3B). The transfer of JAM-A+/+ or JAM-A−/− bonemarrow
DCs into 13-week-old Rip1Tag2 mice resulted in a small but
significant increase in infiltration of JAM-A−/− compared with
that of JAM-A+/+ DCs into the islet tumors (Fig. 3C).
JAM-A expression did not influence other DC functions
such as cytokine production or induction of Th1 polarization
of naive CD4 lymphocytes (Supplementary Fig. S4A and B).
Furthermore, in vitro JAM-A−/− endothelial cells are more
permeable to DCs (Fig. 3D).
The increased infiltration of JAM-A−/− DCs correlated with
higher numbers of CD4 and CD8 leukocytes in pancreatic islet
tumors of Rip1Tag2;JAM-A−/− mice compared with Rip1Tag2;
JAM-A+/+ mice (Fig. 4A and B). Antibodies directed to CD4 and
CD8 cells, which strongly reduced their number in the circula-
tion (Supplementary Fig. S5), abrogated the inhibitory effect of
JAM-A inactivation on tumor incidence and progression, an-
giogenesis, and tumor cell apoptosis (Fig. 4C and D).
Discussion
In this article, we report that the genetic abrogation of
JAM-A expression reduces the formation and progressionFigure 2. Rip1Tag2(RT);JAM-A−/− mice show decreased angiogenesis and increased apoptosis in pancreatic islet tumors. A, representative PECAM1
staining of blood vessels of pancreatic islet tumors of 13-wk-old RT JAM-A+/+ and RT JAM-A−/− mice. Columns, means PECAM1-positive areas per
square millimeter (n = 5 mice); bars, SEM. Bar, 50 μm. B and C, tumor cell proliferation determined by Ki-67 (B) and apoptosis determined by
TUNEL staining (C). Columns, mean positive cells per total tumor cells or per square millimeter, respectively (n = 5 mice); bars, SEM.Cancer Res; 70(5) March 1, 2010 1761
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Published OnlineFirst February 16, 2010; DOI:10.1158/0008-5472.CAN-09-1703Figure 3. JAM-A–null DCs infiltrate pancreatic islet tumors more efficiently than wild-type cells. A, representative pictures and quantification of MHC-class
II+ and CD11c+ DCs and F4/80+ phagocytes in pancreatic islet tumors of RT JAM-A+/+ and RT JAM-A−/− mice. Bar, 100 μm. B, flow cytometry profiles of
CD11b+ and CD11c+ cells in total cell suspensions of islet tumors and peripancreatic lymph nodes. C, quantification of adoptively transferred JAM-A+/+
and JAM-A−/− DCs into pancreatic islet tumors. D, transmigration of DCs through JAM-A+/+ and JAM-A−/− endothelial monolayers. Columns, mean (n = 5);
bars, SEM.Cancer Res; 70(5) March 1, 2010 Cancer Research
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Published OnlineFirst February 16, 2010; DOI:10.1158/0008-5472.CAN-09-1703of β-cell tumors in Rip1Tag2 mice. In this model, tumor cells
do not express JAM-A, and therefore, the observed effects are
likely due to functional changes of the cells of the tumor
stroma. In the absence of JAM-A, tumor angiogenesis in
Rip1Tag2 mice is reduced, supporting previous data on cul-www.aacrjournals.org
American Asso Copyright © 2010 
cancerres.aacrjoDownloaded from tured endothelial cells that implicated a role of JAM-A in an-
giogenesis via αvβ3-integrin activation and fibroblast growth
factor signaling (1, 13, 14). The decrease in tumor vasculari-
zation may be responsible of the increase in tumor cell apo-
ptosis and reduced tumor size. Other groups reported thatFigure 4. Higher infiltration of CD4+ and CD8+ leukocytes in Rip1Tag2(RT);JAM-A−/− mice. A, representative pictures and quantification of CD4+ and CD8+
leukocytes in pancreatic islet tumors of RT JAM-A+/+ and RT JAM-A−/− mice. Columns, mean [n = 5 (20 regions per mouse)]; bars, SEM. Bar, 100 μm.
B, flow cytometry profiles of CD4+ and CD8+ cells in total cell suspensions of tumors and peripancreatic lymph nodes. Columns, mean (n = 5); bars, SEM.
C, percent reduction of tumor number and area in RT JAM-A−/− compared with RT JAM-A+/+ mice on treatment with control or CD4 and CD8
antibodies. D, percent reduction of tumor angiogenesis and percent increase in tumor cell apoptosis by TUNEL staining of tumor sections of RT JAM-A−/−
compared with RT JAM-A+/+ on treatment with control or CD4 and CD8 antibodies. Columns, mean (n = 8 mice per group); bars, SEM.Cancer Res; 70(5) March 1, 2010 1763
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Published OnlineFirst February 16, 2010; DOI:10.1158/0008-5472.CAN-09-1703matrix metalloproteinase-9 expressed in infiltrating neutro-
phils mediates the initial angiogenic switch (15). However,
neutrophil infiltration is rather low in our experimental con-
ditions and does not change in the absence of JAM-A. In con-
trast, ablation of lymphocyte CD4 and CD8 (see below)
abrogated the inhibition of angiogenesis in JAM-A–null mice,
suggesting that the effect may be indirectly mediated by the
immune reaction of the stroma.
Our data also suggest that additional mechanisms evoked
by JAM-A depletion may contribute to inhibition of tumor
growth. In a previously published work, the Rip1Tag2 model
was shown to be quite insensitive to self-reactive lympho-
cytes possibly because of a relatively scarce infiltration of
these cells in the tumor stroma and the inhibitory activity
of the tumor microenvironment (16). In the present article,
we observed a higher rate of DC migration into the tumor,
accompanied by increased infiltration of CD4 and CD8 T-
lymphocytes. In vitro data show that, whereas several DC
functions such as production of cytokines or Th1 activation
were unchanged in the absence of JAM-A, DC transmigration
through JAM-A–null endothelium was increased.
The role of JAM-A in leukocyte transmigration through en-
dothelial cells and in leukocyte motility has been widely in-
vestigated (1–6). Data show that the mechanism of action of
JAM-A is context and cell type dependent (2, 17). This protein
may exert different and, in some cases, even opposite effects
in different cell types. In a previously published work, in the
effort to investigate the mechanism of action of JAM-A, we
found that this molecule may interact with integrins and
modulate their internalization and recycling likely through
the small GTPase Rap-1 (18). The direct or indirect interac-
tions of JAM-A with different types of integrins and in differ-
ent cell types have been previously described (14, 18).
The increase in recruitment of CD4+ and CD8+ lympho-
cytes in the absence of JAM-A is likely mediated by DCs be-
cause lymphocyte infiltration per se in inflammatory tissues
is quite insensitive to or even decreased by JAM-A ablation
(19). DCs may release activating cytokines and chemokines,
which, in turn, attract T lymphocytes. These cells can then
mature within the tumor stroma and prime and boost T cellsCancer Res; 70(5) March 1, 2010
American Asso Copyright © 2010 
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we report here that the decrease in tumor growth is accom-
panied by increased apoptosis of tumor cells, which may be
mediated by cytotoxic CD8 cells. This hypothesis is sup-
ported by the results obtained with blocking CD4 and CD8
antibodies, which abrogate the inhibitory effect of JAM-A ab-
lation on tumor growth and apoptosis.
In other systems, JAM-A promotesmonocyte recruitment at
inflammatory sites (4); however, in JAM-A−/− tumors, we could
not detect any significant decrease in phagocyte infiltration in
the tumor stroma. Because the effects of JAM-A are dependent
on the type of model and inflammatory cytokines implicated
(17), it is possible that in Rip1Tag2 tumors, the inhibitory role
of JAM-A deficiency such as neutrophils and monocytes is
overcome by a strong activation of DCs, CD4, and CD8.
Other studies reported that, in mammary carcinoma cell
lines, JAM-A expression reduced tumor cell migration and in-
vasion (20). Because breast tumor expressed JAM-A, these
events were related to the tumor-associated protein and im-
plicated the JAM-A–dependent regulation of tumor cell-cell
and cell-substrate adhesion, whereas the present study de-
scribes the effects of JAM-A on tumor-associated immune
cells. How these effects of JAM-A may influence the overall
mammary tumor growth in vivo remains to be evaluated.
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